Fair Value Measurements (Narrative) (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent purchase price consideration	$ 8,843,000	$ 3,038,000
Fair value of transfers into or out of Levels 1 and 2	0
Long-term Debt, Gross	14,146,000	14,146,000
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent purchase price consideration	0	0
Debt Instrument, Fair Value Disclosure	14,200,000	$ 14,200,000
4-antibody acquisition [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent purchase price consideration	6,700,000
PhosImmune Inc. [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent purchase price consideration	$ 2,100,000